2552.HK

Hua Medicine (Shanghai) Ltd. [2552.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

2552.HK Stock Summary

Top 10 Correlated ETFs

2552.HK

Top 10 Correlated Stocks

2552.HK

In the News

2552.HK Financial details

Company Rating
-
Market Cap
1.54B
Income
-188.98M
Revenue
70.7M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
177
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-9.61
Forward P/E
-
PEG
2.16
P/S
112.63
P/B
7
P/C
-
P/FCF
-7.7
Quick Ratio
2.6
Current Ratio
4.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-40%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-12.03%
SMA50
33.33%
SMA100
50.35%
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
-56%
ROC
-0.21%
Gross Margin
44%
Oper. Margin
-1134%
Profit Margin
-1158%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.29-3.68
52W High
-26.67%
52W Low
+120%
RSI
52.83
Rel Volume
0.56
Avg Volume
1.04M
Volume
585K
Perf Week
13.99%
Perf Month
-10.93%
Perf Quarter
27.17%
Perf Half Y
27.91%
-
-
-
-
Beta
1.601
-
-
Volatility
0.09%, 0.21%
Prev Close
-0.9%
Price
2.2
Change
1.85%

Something similar

Top by Market Cap
AVGO
APC.DE
BRH.DE
BRK-B
TL0.DE
Top Correlated ETFs
XAD6.MI
3097.HK
3175.HK
SIUS.L
JPHC.PA
Top Correlated Stocks
2348.HK
0393.HK
1378.HK
2256.HK
2488.HK
Similar Market Cap
600193.SS
NITIRAJ.NS
VIS.MC
2231.HK
VSCRX

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 1.04M
  • Market Capitalization 1.54B
  • Employee 177
  • CEO Dr. Li Chen Ph.D.
  • Headquarters Beijing,CN
  • IPO Date 2018-09-14
  • Website https://www.huamedicine.com

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.